Genentech
Executive Summary
Begins clinical trials of an AIDS vaccine based on a recombinant form of the gp 120 envelope protein as a potential treatment for HIV infection. According to Genentech, the study "is being conducted to determine if post-exposure immunization with recombinant gp 120 can significantly boost the immune system of persons infected with HIV." The trial is being conducted at Walter Reed Army Institute of Research in Washington, D.C., and will involve 55 patients studied over a 10-month period. Genentech also reports the company "is currently evaluating the possibility of a separate human pilot study to test recombinant gp 120 as a potential vaccine to protect uninfected individuals against HIV infection".